Generic Name and Formulations:
Ibandronate (as sodium) 150mg; tabs.
Indications for BONIVA:
Prevention and treatment of postmenopausal osteoporosis.
Limitations Of use:
Optimal duration of use has not been determined. For patients at low-risk for fracture: consider drug discontinuation after 3–5yrs.
Swallow whole. Take in the AM with plain (not mineral) water (6–8oz), at least 60mins before the first food, drink, or medication of the day; do not lie down for at least 60mins after. 150mg once monthly (take on the same day each month). If dose is missed, do not take two 150mg tablets within the same week.
Hypocalcemia. Tabs: Esophagus abnormalities which delay esophageal emptying (eg, stricture, achalasia). Inability to stand or sit upright for at least 60mins.
Active upper GI disease; discontinue and reevaluate if signs/symptoms of esophageal reaction occur. Severe renal impairment (CrCl <30mL/min): not recommended. Correct preexisting hypocalcemia, other mineral or bone disturbances before starting. Risk of osteonecrosis of the jaw; consider discontinuing therapy during invasive dental procedures (eg, tooth extraction, implants, surgery). History of bisphosphonate exposure: evaluate for atypical fractures if thigh/groin pain develops; consider withholding therapy until risk/benefit assessment. Ensure adequate Vit. D and calcium intake. Reevaluate periodically. Inj: check renal function before each dose. Pregnancy. Nursing mothers.
Calcium, aluminum, magnesium, other multivalent cations reduce absorption (separate dosing by at least 60mins). Caution with aspirin, NSAIDs, other GI irritants. May interfere with bone-imaging agents. Inj: concomitant nephrotoxic agents; monitor for renal toxicity.
Back pain, dyspepsia, pain in extremity, diarrhea, headache, myalgia; musculoskeletal pain (discontinue if severe), esophagitis, esophageal or gastric ulcer, jaw osteonecrosis, atypical femur fractures. Inj: inj site reactions, flu-like syndrome, anaphylaxis.
Blister pack—3; Kit—1 (prefilled syringe + supplies)
Neurology Advisor Articles
- Erenumab Superior to Placebo for Reducing Migraine Disability, Improving HRQoL
- Managing Status Epilepticus in Palliative Care: Accounting for Patient and Family Experience
- Congress Passes Bill to Fight Opioid Crisis
- Physical Activity Decreases Vascular Comorbidities in Multiple Sclerosis
- Review of Factors Impacting Sport-Related Concussion Headaches
- Anodal tDCS Offers Possible Benefit for Improving Item Recall in Post-Stroke Aphasia
- Hospitalization Tied to Brain Abnormalities in Older Adults
- Spending Often Persists in High-Cost Medicare-Medicaid Eligible
- Skills-Based Intervention Did Not Cut Systolic BP After Stroke, TIA
- High Frequency of Headaches Following Dialysis Associated With BUN and Blood Pressure